Sustiva

This is primarily due to the patent expiry of major drugs such as Sustiva and Combivir in 2012.

THE MEDICAL NEWS 2009

The FDA approved the drug based on a study showing it was as effective as Sustiva, an older HIV drug already on the market.

U.S. approves new HIV drug from Johnson & Johnson 2011

The FDA approved the drug based on a study showing it was as effective as Sustiva, an older HIV drug already on the market.

U.S. approves new HIV drug from Johnson & Johnson 2011

Sales increased for HIV drugs Reyataz and Sustiva, and Baraclude for hepatitis B.

Bristol-Myers Net Rises 76% on Lower Taxes Peter Loftus 2012

Virology drugs Reyataz, Sustiva and Baraclude posted sales gains, while sales of anti-hypertension drugs Avapro and Avalide declined.

Bristol-Myers Profit Slips Peter Loftus 2010

Bristol-Myers posted gains for several other drugs, including HIV treatments Reyataz and Sustiva, and cancer drugs Erbitux and Sprycel.

Bristol-Myers Net Falls, but Plavix Sales Are Up Peter Loftus 2011

In AIDS patients to be effective it must be combined with another drug, like a protease inhibitor or a non-nuke NNRTi like Sustiva.

Charles Karel Bouley: HIV Prevention Drug: Thanks, But No Thanks Charles Karel Bouley 2010

Bristol-Myers's current HIV/AIDS therapies, Reyataz and Sustiva, had sales of more than $2.68 billion world-wide last year, while its hepatitis B treatment, Baraclude, had $734 million in sales.

Bristol-Myers Agrees to Acquire Biotech Company ZymoGenetics Jonathan Rockoff 2010

Earlier use of antiviral drugs like Viread, Sustiva and Combivir would boost sales for their makers.

A Boon For HIV Drugs? 2009

Sales of Bristol's antipsychotic drug Abilify rose 22% to $643 million, while the HIV drug Sustiva had an 11% increase to $312 million.

Bristol Myers, Wyeth Post Higher Profits 2009